Carperitide

Drug Profile

Carperitide

Alternative Names: HANP; hANP(99-126); Human atrial natriuretic peptide; SUN 4936; SUN 4936h; SUN 4936r; SUN Y4936r

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asubio Pharma
  • Developer Asubio Pharma; Asubio Pharmaceuticals; Zeria
  • Class Amino acids; Heart failure therapies; Natriuretic peptides; Peptides
  • Mechanism of Action Atrial peptide agonists; Diuretics; Natriuretic peptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • Discontinued Adult respiratory distress syndrome; Myocardial infarction

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 25 Aug 2015 Discontinued - Phase-III for Myocardial infarction in Japan (IV)
  • 15 Jan 2008 Efficacy and adverse events data from an independent trial in acute myocardial infarction released by Asubio ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top